Riluzole for treating spasticity in patients with chronic traumatic spinal cord injury: Study protocol in the phase ib/iib adaptive multicenter randomized controlled RILUSCI trial - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue PLoS ONE Année : 2023

Riluzole for treating spasticity in patients with chronic traumatic spinal cord injury: Study protocol in the phase ib/iib adaptive multicenter randomized controlled RILUSCI trial

Résumé

Satisfactory treatment is often lacking for spasticity, a highly prevalent motor disorder in patients with spinal cord injury (SCI). Low concentrations of riluzole potently reduce the persistent sodium current, the post-SCI increase in which contributes to spasticity. The repurposing of this drug may therefore constitute a useful potential therapeutic option for relieving SCI patients suffering from chronic traumatic spasticity. Objective RILUSCI is a phase 1b-2b trial designed to assess whether riluzole is a safe and biologically effective means of managing spasticity in adult patients with traumatic chronic SCI.
Fichier principal
Vignette du fichier
journal.pone.0276892.pdf (920.95 Ko) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
Licence

Dates et versions

hal-04087364 , version 1 (03-05-2023)

Licence

Identifiants

Citer

Maëva Cotinat, Isabelle Boquet, Moreno Ursino, Cécile Brocard, Elisabeth Jouve, et al.. Riluzole for treating spasticity in patients with chronic traumatic spinal cord injury: Study protocol in the phase ib/iib adaptive multicenter randomized controlled RILUSCI trial. PLoS ONE, 2023, 18, ⟨10.1371/journal.pone.0276892⟩. ⟨hal-04087364⟩
47 Consultations
17 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More